COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Low Dose Aspirin Studied With the AggreGuide

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01603966
Recruitment Status : Completed
First Posted : May 23, 2012
Last Update Posted : July 17, 2012
Information provided by (Responsible Party):
Edward R. Teitel, M.D., Aggredyne, Inc.

Brief Summary:
This study is to determine whether the AggreGuide platelet aggregometer can discern the effect of low dose aspirin on subjects platelet aggregation using arachidonic acid as the agonist.

Condition or disease
Platelet Aggregation

Layout table for study information
Study Type : Observational
Actual Enrollment : 13 participants
Observational Model: Case-Crossover
Time Perspective: Prospective
Official Title: Low Dose Aspirin Study With the AggreGuide
Study Start Date : April 2012
Actual Primary Completion Date : June 2012
Actual Study Completion Date : June 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Aspirin

Biospecimen Retention:   None Retained
whole blood

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
community sample

Inclusion Criteria:

  • adults

Exclusion Criteria:

  • aspirin contraindications
  • anticoagulants
  • aspirin past week

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01603966

Layout table for location information
United States, Texas
Aggredyne, Inc.
Houston, Texas, United States, 77099
Sponsors and Collaborators
Edward R. Teitel, M.D.
Layout table for investigator information
Principal Investigator: Edward R. Teitel, MD Aggredyne, Inc.
Layout table for additonal information
Responsible Party: Edward R. Teitel, M.D., CEO, Aggredyne, Inc. Identifier: NCT01603966    
Other Study ID Numbers: Val-030
First Posted: May 23, 2012    Key Record Dates
Last Update Posted: July 17, 2012
Last Verified: July 2012
Keywords provided by Edward R. Teitel, M.D., Aggredyne, Inc.: